BioCentury | Jun 26, 2019
Distillery Therapeutics

Induction of NFE2L2 activity for Alzheimer's disease

...low NFE2L2 transcript levels were associated with larger β amyloid plaques. In mice with AD, sulforaphane...
BioCentury | May 9, 2018
Distillery Therapeutics

Dermatology

...INDICATION: Dermatology Mouse and cell culture studies suggest RHBDF2 inhibition or sulforaphane could help treat palmoplantar...
...sulforaphane (SFX-01, Sulforadex), a complex of sulforaphane and α-cyclodextrin in a stable powder developed using Sulforadex...
...London, U.K. email: d.p.kelsell@qmul.ac.uk CONTACT: Anissa Chikh, same affiliation as above email: a.chikh@qmul.ac.uk Chris Lieu sulforaphane (SFX-01, Sulforadex) Queen...
BioCentury | Jan 18, 2017
Clinical News

SFX-01: Ph II STEM started

...Evgen began the open-label, European Phase II STEM trial to evaluate 300 mg oral SFX-01 twice...
...Molecular target: NA Description: Complex of sulforaphane and alpha-cyclodextrin in a stable powder developed using Sulforadex...
...PFS), overall survival (OS) and time to next treatment Status: Phase II started Milestone: NA Julian Zhu SFX-01 sulforaphane Evgen...
BioCentury | Jan 12, 2017
Clinical News

SFX-01: Ph II SAS ongoing

...An independent DSMB recommended continuation of the double-blind, placebo-controlled, U.K. Phase II SAS trial of SFX-01...
...a nasogastric tube based on an interim safety review. The trial is evaluating 300 mg SFX-01...
...Molecular target: NA Description: Complex of sulforaphane and alpha-cyclodextrin in a stable powder developed using Sulforadex...
BioCentury | Jun 23, 2016
Distillery Therapeutics

Therapeutics: Nuclear factor (erythroid-derived 2)-like 2 (NFE2L2; NRF2)

...Dermatology INDICATION: Dermatology Patient sample and mouse studies suggest the NFE2L2 activator sulforaphane could help treat...
...skin samples from healthy volunteers. In a mouse model of pachyonychia congenita, topical application of sulforaphane...
...include testing sulforaphane in other models of pachyonychia congenita. Evgen Pharma plc has sulforaphane ( SFX-01...
BioCentury | May 9, 2016
Clinical News

Sulforaphane: Phase II started

...oral SFX-01 twice daily for up to 28 days plus nimodipine in about 90 patients. SFX-01...
...Molecular target: NA Description: Complex of sulforaphane and alpha-cyclodextrin in a stable powder developed using Sulforadex...
BioCentury | Dec 21, 2015
Company News

Spanish National Research Council, University of Seville, Evgen Pharma deal

...Evgen exercised a 2013 option to acquire exclusive, worldwide rights to 60 sulforaphane analogs from the...
...plus royalties that will not exceed 1%. Evgen’s SFX-01 , a synthetic, stabilized form of sulforaphane...
BioCentury | Dec 5, 2014
Financial News

Evgen to list on AIM

...I/II testing of SFX-01 in prostate and breast cancers and Phase II testing of the sulforaphane...
BioCentury | May 22, 2014
Cover Story

Ob(nox)ious fibrosis

...to elevated superoxide levels to be impeded specifically in fibrotic cells of aged mice. Accordingly, sulforaphane...
BioCentury | Aug 12, 2010
Distillery Therapeutics

Indication: Neurology

...did no injury. In the same models, Nox2 knockout or treatment with the generic antioxidant sulforaphane...
Items per page:
1 - 10 of 11